Your browser doesn't support javascript.
loading
Interferon α/ß Receptor-Deficient Mice as a Model for Ebola Virus Disease.
Brannan, Jennifer M; Froude, Jeffery W; Prugar, Laura I; Bakken, Russell R; Zak, Samantha E; Daye, Sharon P; Wilhelmsen, Catherine E; Dye, John M.
Afiliação
  • Brannan JM; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Froude JW; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Prugar LI; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Bakken RR; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Zak SE; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Daye SP; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Wilhelmsen CE; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
  • Dye JM; US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland.
J Infect Dis ; 212 Suppl 2: S282-94, 2015 Oct 01.
Article em En | MEDLINE | ID: mdl-25943199
ABSTRACT
A major obstacle in ebolavirus research is the lack of a small-animal model for Sudan virus (SUDV), as well as other wild-type (WT) ebolaviruses. Here, we expand on research by Bray and by Lever et al suggesting that WT ebolaviruses are pathogenic in mice deficient for the type 1 interferon (IFN) α/ß receptor (IFNα/ßR-/-). We examined the disease course of several WT ebolaviruses Boneface (SUDV/Bon) and Gulu variants of SUDV, Ebola virus (EBOV), Bundibugyo virus (BDBV), Taï Forest virus, and Reston virus (RESTV). We determined that exposure to WT SUDV or EBOV results in reproducible signs of disease in IFNα/ßR-/- mice, as measured by weight loss and partial lethality. Vaccination with the SUDV or EBOV glycoprotein (GP)-expressing Venezuelan equine encephalitis viral replicon particle vaccine protected these mice from SUDV/Bon and EBOV challenge, respectively. Treatment with SUDV- or EBOV-specific anti-GP antibodies protected mice from challenge when delivered 1-3 days after infection. Serial sampling experiments revealed evidence of disseminated intravascular coagulation in the livers of mice infected with the Boneface variant of SUDV, EBOV, and BDBV. Taken together, these data solidify the IFNα/ßR-/- mouse as an important and useful model for the study of WT EBOV disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Virulência / Doença pelo Vírus Ebola / Ebolavirus / Receptor de Interferon alfa e beta Limite: Animals Idioma: En Revista: J Infect Dis Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Virulência / Doença pelo Vírus Ebola / Ebolavirus / Receptor de Interferon alfa e beta Limite: Animals Idioma: En Revista: J Infect Dis Ano de publicação: 2015 Tipo de documento: Article